The markets are buzzing with speculation following reports that President Trump is considering reclassifying cannabis from a Schedule I to a Schedule III drug. While this is not the same as full federal legalization, it could reshape the industry in meaningful ways. For investors who have endured years of volatility in cannabis stocks, this potential policy shift may open new doors to profitability and growth.
Why Reclassifying Cannabis Matters
Currently, cannabis sits in Schedule I alongside heroin and LSD, defined as having no accepted medical use. By reclassifying cannabis into Schedule III—where drugs such as ketamine and testosterone reside the government would formally acknowledge its medicinal potential. This change carries practical implications: companies would gain relief from IRS tax code 280E, which prevents cannabis operators from deducting ordinary business expenses. Without this burden, businesses could unlock significant free cash flow, improving balance sheets and investor confidence.
Copyright
©420 Intel